EDITORIAL

Changes in the JCO

JCO Jan 1 1997: 1. [PDF]

ARTICLES
Economic analyses of new technologies: the case of stem-cell transplantation
TM Waters, CL Bennett, and JM Vose
JCO Jan 1 1997: 2–4. [PDF]
	Economic analysis of a randomized clinical trial to compare filgrastim- mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma
	TJ Smith, BE Hillner, N Schmitz, DC Linch, P Dreger, AH Goldstone, MA Boogaerts, A Ferrant, H Link, A Zander, S Yanovich, R Kitchin, and MH Erder
	JCO Jan 1 1997: 5–10. [Abstract] [PDF]
	Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies
	BR Meisenberg, WE Miller, R McMillan, M Callaghan, C Sloan, T Brehm, MP Kosty, J Kroener, R Longmire, A Saven, and LD Piro
	JCO Jan 1 1997: 11–17. [Abstract] [PDF]
	Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies
	CR Kusnierz-Glaz, PG Schlegel, RM Wong, JR Schriber, NJ Chao, MD Amylon, WW Hu, RS Negrin, Y Lee, KG Blume, and GD Long
	JCO Jan 1 1997: 18–25. [Abstract] [PDF]
	Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study
	W Stock, CA Westbrook, B Peterson, DC Arthur, TP Szatrowski, RT Silver, DA Sher, D Wu, MM Le Beau, CA Schiffer, and CD Bloomfield
	JCO Jan 1 1997: 26–36. [Abstract] [PDF]
	Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia
	A Saven, T Lee, M Schlutz, A Jacobs, D Ellison, R Longmire, and L Piro
	JCO Jan 1 1997: 37–43. [Abstract] [PDF]
	Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia
	K Seiter, EJ Feldman, HD Halicka, F Traganos, Z Darzynkiewicz, D Lake, and T Ahmed
	JCO Jan 1 1997: 44–51. [Abstract] [PDF]
	Case/control study of the role of splenectomy in chronic lymphocytic leukemia
	JF Seymour, JD Cusack, SA Lerner, RE Pollock, and MJ Keating
	JCO Jan 1 1997: 52–60. [Abstract] [PDF]
	Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity
	K Sorensen, G Levitt, C Bull, J Chessells, and I Sullivan
	JCO Jan 1 1997: 61–68. [Abstract] [PDF]
	Preservation of the bladder in patients with rhabdomyosarcoma
	R Heyn, WA Newton, RB Raney, A Hamoudi, C Bagwell, T Vietti, M Wharam, E Gehan, and HM Maurer
	JCO Jan 1 1997: 69–75. [Abstract] [PDF]
	Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group
	AJ Provisor, LJ Ettinger, JB Nachman, MD Krailo, JT Makley, EJ Yunis, AG Huvos, DL Betcher, ES Baum, CT Kisker, and JS Miser
	JCO Jan 1 1997: 76–84. [Abstract] [PDF]
	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children
	GP Tonini, L Boni, A Pession, D Rogers, A Iolascon, G Basso, L Cordero di Montezemolo, F Casale, A Pession, P Perri, K Mazzocco, P Scaruffi, C Lo Cunsolo, N Marchese, C Milanaccio, M Conte, P Bruzzi, and B De Bernardi
	JCO Jan 1 1997: 85–93. [Abstract] [PDF]
	Ketamine-midazolam versus meperidine-midazolam for painful procedures in pediatric oncology patients
	CM Marx, J Stein, MK Tyler, ML Nieder, SB Shurin, and JL Blumer
	JCO Jan 1 1997: 94–102. [Abstract] [PDF]
	Proposal for classifying the acute emetogenicity of cancer chemotherapy
	PJ Hesketh, MG Kris, SM Grunberg, T Beck, JD Hainsworth, G Harker, MS Aapro, D Gandara, and CM Lindley
	JCO Jan 1 1997: 103–109. [Abstract] [PDF]
	Patient preferences for oral versus intravenous palliative chemotherapy
	G Liu, E Franssen, MI Fitch, and E Warner
	JCO Jan 1 1997: 110–115. [Abstract] [PDF]
	Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group
	D Osoba, B Zee, J Pater, D Warr, J Latreille, and L Kaizer
	JCO Jan 1 1997: 116–123. [Abstract] [PDF]
	Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research
	JCO Jan 1 1997: 124–130. [Abstract] [PDF]
	Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy
	J Vinholes, CY Guo, OP Purohit, R Eastell, and RE Coleman
	JCO Jan 1 1997: 131–138. [Abstract] [PDF]
	Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
	D Caillot, O Casasnovas, A Bernard, JF Couaillier, C Durand, B Cuisenier, E Solary, F Piard, T Petrella, A Bonnin, G Couillault, M Dumas, and H Guy
	JCO Jan 1 1997: 139–147. [Abstract] [PDF]
	Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
	JR Murren, S Anderson, J Fedele, G Pizzorno, D Belliveau, D Zelterman, BA Burtness, I Tocino, SD Flynn, D Beidler, and YC Cheng
	JCO Jan 1 1997: 148–157. [Abstract] [PDF]
	Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients
	HI Robins, D Rushing, M Kutz, KD Tutsch, CL Tiggelaar, D Paul, D Spriggs, C Kraemer, W Gillis, C Feierabend, RZ Arzoomanian, W Longo, D Alberti, F d'Oleire, RP Qu, G Wilding, and JA Stewart
	JCO Jan 1 1997: 158–164. [Abstract] [PDF]
	Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study
	GA Omura, JA Blessing, L Vaccarello, ML Berman, DL Clarke-Pearson, DG Mutch, and B Anderson
	JCO Jan 1 1997: 165–171. [Abstract] [PDF]
	Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125
	GJ Rustin, AE Nelstrop, M Crawford, J Ledermann, HE Lambert, R Coleman, J Johnson, H Evans, S Brown, and W Oster
	JCO Jan 1 1997: 172–176. [Abstract] [PDF]
	Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study
	S O'Reilly, GF Fleming, SD Barker, JR Walczak, MA Bookman, WP McGuire, 3rd, RJ Schilder, RD Alvarez, DK Armstrong, IR Horowitz, RF Ozols, and EK Rowinsky
	JCO Jan 1 1997: 177–186. [Abstract] [PDF]
	Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
	D Fennelly, C Aghajanian, F Shapiro, C O'Flaherty, M McKenzie, C O'Connor, W Tong, L Norton, and D Spriggs
	JCO Jan 1 1997: 187–192. [Abstract] [PDF]
	Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study
	A Jakobsen, K Bertelsen, JE Andersen, H Havsteen, P Jakobsen, KA Moeller, K Nielsen, E Sandberg, and I Stroeyer
	JCO Jan 1 1997: 193–198. [Abstract] [PDF]
	Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer
	G Cavaletti, G Bogliun, V Crespi, L Marzorati, A Zincone, M Marzola, S Rota, A Galli, P Tredici, and G Tredici
	JCO Jan 1 1997: 199–206. [Abstract] [PDF]
	Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial
	H Bartelink, RD Rubens, E van der Schueren, and R Sylvester
	JCO Jan 1 1997: 207–215. [Abstract] [PDF]
	Compliance with practice guidelines for node-negative breast cancer
	A Olivotto, AJ Coldman, TG Hislop, CH Trevisan, J Kula, V Goel, and C Sawka
	JCO Jan 1 1997: 216–222. [Abstract] [PDF]
	Complications after treatment with external-beam irradiation in early- stage prostate cancer patients: a prospective multiinstitutional outcomes study
	CJ Beard, KJ Propert, PP Rieker, JA Clark, I Kaplan, PW Kantoff, and JA Talcott
	JCO Jan 1 1997: 223–229. [Abstract] [PDF]
	Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations
	WR Lee, GE Hanks, and A Hanlon
	JCO Jan 1 1997: 230–238. [Abstract] [PDF]
	Fertility after chemotherapy for testicular germ cell cancers
	H Lampe, A Horwich, A Norman, J Nicholls, and DP Dearnaley
	JCO Jan 1 1997: 239–245. [Abstract] [PDF]
	Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
	MJ O'Connell, JA Mailliard, MJ Kahn, JS Macdonald, DG Haller, RJ Mayer, and HS Wieand
	JCO Jan 1 1997: 246–250. [Abstract] [PDF]
	Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
	P Rougier, R Bugat, JY Douillard, S Culine, E Suc, P Brunet, Y Becouarn, M Ychou, M Marty, JM Extra, J Bonneterre, A Adenis, JF Seitz, G Ganem, M Namer, T Conroy, S Negrier, Y Merrouche, F Burki, M Mousseau, P Herait, and M Mahjoubi
	JCO Jan 1 1997: 251–260. [Abstract] [PDF]
	Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
	A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, and M Meehan
	JCO Jan 1 1997: 261–267. [Abstract] [PDF]
	Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials
	BG Haffty, YH Son, R Papac, CT Sasaki, JB Weissberg, D Fischer, S Rockwell, AC Sartorelli, and JJ Fischer
	JCO Jan 1 1997: 268–276. [Abstract] [PDF]
	Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study [published erratum appears in J Clin Oncol 1997 Feb;15(2):866]
	M al-Sarraf, K Martz, A Herskovic, L Leichman, JS Brindle, VK Vaitkevicius, J Cooper, R Byhardt, L Davis, and B Emami
	JCO Jan 1 1997: 277–284. [Abstract] [PDF]
	Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study
	S Rodenhuis, L Boerrigter, B Top, RJ Slebos, WJ Mooi, L van't Veer, and N van Zandwijk
	JCO Jan 1 1997: 285–291. [Abstract] [PDF]
	Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer
	K Kubota, Y Nishiwaki, R Kakinuma, F Hojo, T Matsumoto, H Ohmatsu, I Sekine, M Yokozaki, K Goto, N Ebi, and T Kodama
	JCO Jan 1 1997: 292–296. [Abstract] [PDF]
	Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study
	L Crino, G Scagliotti, M Marangolo, F Figoli, M Clerici, F De Marinis, F Salvati, G Cruciani, L Dogliotti, F Pucci, A Paccagnella, V Adamo, G Altavilla, P Incoronato, M Trippetti, AM Mosconi, A Santucci, S Sorbolini, C Oliva, and M Tonato
	JCO Jan 1 1997: 297–303. [Abstract] [PDF]
	Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer
	F Oshita, K Noda, Y Nishiwaki, A Fujita, Y Kurita, T Nakabayashi, K Tobise, S Abe, S Suzuki, I Hayashi, Y Kawakami, T Matsuda, S Tsuchiya, S Takahashi, T Tamura, and N Saijo
	JCO Jan 1 1997: 304–309. [Abstract] [PDF]
	Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non- small-cell lung cancer
	FV Fossella, SM Lippman, DM Shin, P Tarassoff, M Calayag-Jung, R Perez-Soler, JS Lee, WK Murphy, B Glisson, E Rivera, and WK Hong
	JCO Jan 1 1997: 310–316. [Abstract] [PDF]
	Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre
	MT Huizing, G Giaccone, LJ van Warmerdam, H Rosing, PJ Bakker, JB Vermorken, PE Postmus, N van Zandwijk, MG Koolen, WW ten Bokkel Huinink, WJ van der Vijgh, FJ Bierhorst, A Lai, O Dalesio, HM Pinedo, CH Veenhof, and JH Beijnen
	JCO Jan 1 1997: 317–329. [Abstract] [PDF]
	Trading treatment toxicity for survival in locally advanced non-small cell lung cancer
	MD Brundage, JR Davidson, and WJ Mackillop
	JCO Jan 1 1997: 330–340. [Abstract] [PDF]
	Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma
	AT Stopeck, EM Hersh, ET Akporiaye, DT Harris, T Grogan, E Unger, J Warneke, SF Schluter, and S Stahl
	JCO Jan 1 1997: 341–349. [Abstract] [PDF]
	Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma
	L Guillou, JM Coindre, F Bonichon, BB Nguyen, P Terrier, F Collin, MO Vilain, AM Mandard, V Le Doussal, A Leroux, J Jacquemier, H Duplay, X Sastre-Garau, and J Costa
	JCO Jan 1 1997: 350–362. [Abstract] [PDF]
	Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients
	LE Smeele, PJ Kostense, I van der Waal, and GB Snow
	JCO Jan 1 1997: 363–367. [Abstract] [PDF]
	Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation
	AF Sobrero, C Aschele, and JR Bertino
	JCO Jan 1 1997: 368–381. [Abstract] [PDF]
	Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm
	EJ Small and NJ Vogelzong
	JCO Jan 1 1997: 382–388. [Abstract] [PDF]
	Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors
	YM Rustum, A Harstrick, S Cao, U Vanhoefer, MB Yin, H Wilke, and S Seeber
	JCO Jan 1 1997: 389–400. [Abstract] [PDF]
The physician and unorthodox cancer therapies. The American Society of Clinical Oncology
JCO Jan 1 1997: 401–406. [PDF]
Pyoderma gangrenosum
T Takvorian, A Skarin, and R Johnson
JCO Jan 1 1997: 407. [PDF]
Antisense oligonucleotides targeting p53
C Barton and N Lemoine
JCO Jan 1 1997: 408a. [PDF]
Two doses of paclitaxel and statistical analysis: try, try, try again
W Akerley
JCO Jan 1 1997: 408b–409. [PDF]
Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections?
LH Einhorn
JCO Jan 1 1997: 409–410. [PDF]
Chemotherapy with mitoxantrone in hormone-refractory prostate cancer
AE Denes
JCO Jan 1 1997: 410–411. [PDF]
Prognostic factors in early-stage Hodgkin's disease
AH Sarris
JCO Jan 1 1997: 411–412. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.